Seewaldt and Buermeyer awarded grand prize from the Global Challenge to Prevent Breast Cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Victoria Seewaldt
Nancy Buermeyer
Michele Atlan

The Global Challenge to Prevent Breast Cancer has awarded:

  • The Grand Prize (Researcher Category) to Victoria Seewaldt, professor and chair of Population Sciences at City of Hope, who, with Chris Sistrunk of the SoCAL STEM and Community Outread Team, proposed STEM education to help prevent breast cancer.

  • The Grand Prize (Advocate Category) to Nancy Buermeyer, senior policy strategist at Breast Cancer Prevention Partners, who, with co-author Janet Nudelman, advocates reducing emissions at major ports to lower breast cancer risk.

  • In addition to the two Grand Prize winners chosen by a judging committee of experts and advocates, those in attendance and watching online also had their say, voting on an Audience Choice Award. The winner, Michele Atlan, vice president at the Breast Cancer Care and Research Fund, proposed a novel way to repackage natural ingredients to aid prevention efforts.

Started by the California Breast Cancer Research Program last fall, the Global Challenge was designed to uncover transformative prevention research ideas, and address the staggering statistic that, despite treatment advancements, people continue to be diagnosed with breast cancer at rates that have remained essentially unchanged over the past three decades.

Finalists were selected from dozens of applications that were submitted to the Global Challenge and competed at the Idea Showcase and Competition in San Francisco.

The ideas presented at the Global Challenge Idea Showcase and Competition will inform more than $15 million in funding that CBCRP will devote to breast cancer prevention research over the next five years.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login